• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Barbara Savoldo, Carlos Almeida Ramos, +13 authors Gianpietro Dotti
  • Medicine, Biology
  • The Journal of clinical investigation
  • 2011 (First Publication: 2 May 2011)
  • Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation ofContinue Reading
  • Martin A Pule, Barbara Savoldo, +13 authors Malcolm K. Brenner
  • Medicine
  • Nature Medicine
  • 2008 (First Publication: 1 November 2008)
  • Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor–associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack theContinue Reading
  • C. R. Y. Cruz, K. P. Micklethwaite, +20 authors Gianpietro Dotti
  • Medicine
  • Blood
  • 2013 (First Publication: 24 October 2013)
  • Autologous T cells expressing a CD19-specific chimeric antigen receptor (CD19.CAR) are active against B-cell malignancies, but it is unknown whether allogeneic CD19.CAR T cells are safe or effective.Continue Reading
  • Valentina Cifuentes Hoyos, Barbara Savoldo, +7 authors Gianpietro Dotti
  • Biology, Medicine
  • Leukemia
  • 2010 (First Publication: 14 April 2010)
  • T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies. Because the in vivo survival, expansion andContinue Reading
  • Juan A. Fuentes Vera, Barbara Savoldo, +8 authors Gianpietro Dotti
  • Biology, Medicine
  • Blood
  • 2006 (First Publication: 1 December 2006)
  • There has been interest in generating T cells expressing chimeric artificial receptors (CARs) targeting CD19/CD20 antigens to treat B-cell lymphomas. If successful, however, this approach wouldContinue Reading